Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease

Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group

(2015) Bruce H. Cohen et al.   PEDIATRIC NEUROLOGY

Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial

(2014) G. Cefalo et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

(2013) Q. T. Ostrom et al.   NEURO-ONCOLOGY

High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma

(2011) I. J. Dunkel et al.   NEURO-ONCOLOGY

Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors

(2008) A Marachelian et al.   BONE MARROW TRANSPLANTATION

Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: Outcome compared with conventional chemotherapy: A report from the Children's Oncology Group

(2008) Jonathan L. Finlay et al.   PEDIATRIC BLOOD & CANCER

Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols

(2008) Girish Dhall et al.   PEDIATRIC BLOOD & CANCER